ClinicalTrials.Veeva

Menu

Prevention of Anastomotic Leak in Gastrointestinal (GI) Anastomosis With the Application of Tisseal in the Anastomotic Line

H

Hospital General Universitario Gregorio Marañon

Status and phase

Unknown
Phase 4

Conditions

Anastomotic Leak

Treatments

Drug: Fibrin glue

Study type

Interventional

Funder types

Other

Identifiers

NCT01306851
PROTTISUCOL-001

Details and patient eligibility

About

The anastomotic leak is one of the most feared complications in abdominal surgery. Certain control methods have been described but the incidence of that complication remains high and is the first cause of mortality in operations where gut anastomosis are performed.

With the aim to prove that the use of fibrin glue in the gut anastomosis can improve gut cicatrization, the investigators started the recruitment of patients to that clinical trial in 2007 with the study hypothesis that patients with a gut anastomosis where fibrin glue was used, had less anastomotic leaks than that where the fibrin glue was not used.

The investigators have calculated the number of patients necessaries to have statistical significant differences in 200 patients with a rate anastomotic leak expected to be higher than 10%.

The study include all the patients that usually arrive to our surgery department and that are expected to have a high risk gut anastomosis: rectal anastomosis, GI anastomosis in the obese patient, small bowel anastomosis in the obstructed one and esophageal anastomosis.

The study is randomized, simple blind where the patient does not know if they are in the fibrin glue group or not, and prospectively analyzed. All the clinical and laboratory or radiographic finds relative to the occurrence of an anastomotic leak are recorded.

Enrollment

200 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients undergoing GI surgery where a high risk anastomosis is preview to be done

Exclusion criteria

  • Haemodynamic instability
  • Advanced oncologic disease
  • Proteins below 4 gr/ml

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

200 participants in 1 patient group

Fibrin glue
Active Comparator group
Treatment:
Drug: Fibrin glue

Trial contacts and locations

1

Loading...

Central trial contact

Lago Jesus, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems